Apellis Pharmaceuticals Inc (NAS:APLS)
$ 40.49 0.81 (2.04%) Market Cap: 4.91 Bil Enterprise Value: 4.60 Bil PE Ratio: 0 PB Ratio: 18.40 GF Score: 38/100

Apellis Pharmaceuticals Inc Sobi Strategic Collaboration Conference Call Transcript

Oct 27, 2020 / 12:30PM GMT
Release Date Price: $35.53 (-0.92%)
Operator

Thank you, everyone, and welcome to the Apellis Pharmaceuticals conference call to discuss their collaboration with Sobi. Today's call is being recorded. At this time, I'd like to turn the call over to Tracy Vineis, Vice President of Communications at Apellis.

Tracy Vineis
Apellis Pharmaceuticals, Inc. - VP of Corporate Affairs

Good morning, and thank you for joining us to discuss Apellis' strategic collaboration with Sobi for systemic pegcetacoplan. For those participating by conference call, slides are available via webcast at apellis.com.

Before we begin, I would like to point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.

On today's call, I am joined by Co-Founder and Chief Executive Officer, Dr. Cedric Francois, who will discuss our new collaboration with Sobi. Joining us

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot